About this trial
The aim is to investigate whether screening with long-term ECG monitoring in individuals with elevated NT-proBNP leads to a lower incidence of ischeamic stroke and death from vascular causes. The project is a sub-study within the 8th wave of the population based Tromsø Study. Information on previous diseases, medication use, and risk factors is collected through questionnaires, blood samples, and measurements of height, weight, blood pressure, and ECG.
A total of 4,000 individuals with NT-proBNP levels above the median, without previously known atrial fibrillation (AF) or ongoing anticoagulation therapy, will be randomized to either long-term heart rhythm monitoring (7 days) or a control group without long-term ECG monitoring (2,000 in each group). Individuals with AF in the intervention group will be offered anticoagulation therapy in accordance with current guidelines.
The intervention group and the control group will be compared with regards to incident stroke and death within a 6-year follow-up period. Information on endpoints and anticoagulation use will be obtained through linkage to national registries.
Eligibility criteria
Qualifiers
Age ≥40 years
NT-proBNP> median level
Informed consent for participation
Disqualifiers
History of AF (self-reported)
Use of anticoagulation therapy
Pacemaker/CRT device
No available smart phone
Trial design
Treatments tested in this trial
- Long term heart rythm monitoring by ECG247
Treatment groups
Sponsors and collaborators
University Hospital of North Norway
Lead sponsor
UiT The Arctic University of Norway
Collaborator